CN103347864B - 用于治疗由Lp-PLA2介导的疾病或病症的嘧啶酮化合物 - Google Patents

用于治疗由Lp-PLA2介导的疾病或病症的嘧啶酮化合物 Download PDF

Info

Publication number
CN103347864B
CN103347864B CN201180066903.4A CN201180066903A CN103347864B CN 103347864 B CN103347864 B CN 103347864B CN 201180066903 A CN201180066903 A CN 201180066903A CN 103347864 B CN103347864 B CN 103347864B
Authority
CN
China
Prior art keywords
methyl
phenyl
oxy
trifluoromethyl
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201180066903.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN103347864A (zh
Inventor
金赟
万泽红
张清
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45440490&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN103347864(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Priority to CN201180066903.4A priority Critical patent/CN103347864B/zh
Publication of CN103347864A publication Critical patent/CN103347864A/zh
Application granted granted Critical
Publication of CN103347864B publication Critical patent/CN103347864B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56—One oxygen atom and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201180066903.4A 2010-12-06 2011-12-05 用于治疗由Lp-PLA2介导的疾病或病症的嘧啶酮化合物 Expired - Fee Related CN103347864B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201180066903.4A CN103347864B (zh) 2010-12-06 2011-12-05 用于治疗由Lp-PLA2介导的疾病或病症的嘧啶酮化合物

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN2010079465 2010-12-06
CNPCT/CN2010/079465 2010-12-06
CN201180066903.4A CN103347864B (zh) 2010-12-06 2011-12-05 用于治疗由Lp-PLA2介导的疾病或病症的嘧啶酮化合物
PCT/EP2011/071690 WO2012076435A1 (en) 2010-12-06 2011-12-05 Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by lp - pla2

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201410575164.7A Division CN104478812A (zh) 2010-12-06 2011-12-05 用于治疗由Lp-PLA2介导的疾病或病症的嘧啶酮化合物

Publications (2)

Publication Number Publication Date
CN103347864A CN103347864A (zh) 2013-10-09
CN103347864B true CN103347864B (zh) 2016-08-10

Family

ID=45440490

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180066903.4A Expired - Fee Related CN103347864B (zh) 2010-12-06 2011-12-05 用于治疗由Lp-PLA2介导的疾病或病症的嘧啶酮化合物

Country Status (24)

Country Link
US (4) US8637536B2 (enExample)
EP (1) EP2649053B1 (enExample)
JP (1) JP5886310B2 (enExample)
KR (1) KR101861883B1 (enExample)
CN (1) CN103347864B (enExample)
AR (1) AR084153A1 (enExample)
AU (1) AU2011340690C1 (enExample)
BR (1) BR112013013898B1 (enExample)
CA (1) CA2820408C (enExample)
CL (1) CL2013001604A1 (enExample)
CO (1) CO6801726A2 (enExample)
CR (1) CR20130264A (enExample)
DO (1) DOP2013000130A (enExample)
EA (1) EA023796B1 (enExample)
ES (1) ES2559224T3 (enExample)
IL (1) IL226473A0 (enExample)
MX (1) MX2013006342A (enExample)
PE (1) PE20140421A1 (enExample)
PH (1) PH12013501089A1 (enExample)
SG (1) SG190830A1 (enExample)
TW (1) TW201307324A (enExample)
UY (1) UY33766A (enExample)
WO (1) WO2012076435A1 (enExample)
ZA (1) ZA201303560B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8349577B2 (en) * 2009-04-23 2013-01-08 Research Foundation For Mental Hygiene, Inc. Method for evaluating blood-neural barrier permeability
EP2649050A4 (en) * 2010-12-06 2014-04-23 Glaxo Group Ltd LINKS
CN103347864B (zh) * 2010-12-06 2016-08-10 葛兰素集团有限公司 用于治疗由Lp-PLA2介导的疾病或病症的嘧啶酮化合物
CN103906744A (zh) 2011-09-01 2014-07-02 葛兰素集团有限公司 新晶型
JP6037277B2 (ja) * 2012-12-19 2016-12-07 国立研究開発法人農業・食品産業技術総合研究機構 オーキシン生合成阻害剤
US9296755B2 (en) * 2013-01-25 2016-03-29 Glaxosmithkline Intellectual Property Development Limited 3,4-dihydro-1H-pyrimido[1,6-a]pyrimidin-6(2H)-one compounds and their therapeutic applications
EP2764866A1 (en) 2013-02-07 2014-08-13 IP Gesellschaft für Management mbH Inhibitors of nedd8-activating enzyme
EP3036222A2 (en) * 2013-08-23 2016-06-29 Virginia Commonwealth University Ester nitrates derivatives of aromatic aldehydes with multiple pharmalogic properties to treat sickle cell disease
GB201322602D0 (en) * 2013-12-19 2014-02-05 Almac Discovery Ltd Pharmaceutical compounds
CN103896906A (zh) * 2014-02-28 2014-07-02 苏州维泰生物技术有限公司 一种农药咯菌腈中间体的新合成方法
ES2748324T3 (es) * 2014-07-04 2020-03-16 Japan Tobacco Inc Método para producir un compuesto de indol
WO2016012916A1 (en) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2
WO2016012917A1 (en) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2
CN106188063A (zh) * 2015-05-08 2016-12-07 中国科学院上海药物研究所 用作Lp-PLA2抑制剂的双环类化合物、其制备方法及医药用途
CN110218712B (zh) * 2016-06-02 2021-08-03 天津科技大学 磷脂酶d突变体及其在制备磷脂酸、磷脂酰丝氨酸中的应用
US11464775B2 (en) 2017-08-15 2022-10-11 Agios Pharmaceuticals, Inc. Pyruvate kinase modulators and use thereof
MA58170B1 (fr) * 2019-12-23 2024-10-31 Sitryx Therapeutics Limited Dérivés carboxy avec des proprietes anti-inflammatoires
CN111533699B (zh) * 2020-05-27 2023-12-01 龙曦宁（上海）医药科技有限公司 一种2-（三氟甲基）嘧啶-5-醇的合成方法
US20250154153A1 (en) * 2022-08-04 2025-05-15 4B Technologies (Beijing) Co., Limited Dihydroimidazo-pyrimidinone compounds as lp-pla2 inhibitors and use thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000010980A1 (en) * 1998-08-21 2000-03-02 Smithkline Beecham Plc Pyrimidinone derivatives for the treatment of atherosclerosis
WO2000068208A1 (en) * 1999-05-05 2000-11-16 Smithkline Beecham Plc Pyrimidinones derivatives for the treatment of atherosclerosis
CN1358175A (zh) * 1999-05-01 2002-07-10 史密丝克莱恩比彻姆有限公司 嘧啶酮化合物
CN1418199A (zh) * 2000-02-16 2003-05-14 史密斯克莱·比奇曼公司 作为ldl－pla2抑制剂的嘧啶－4－酮衍生物

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9421816D0 (en) 1994-10-29 1994-12-14 Smithkline Beecham Plc Novel compounds
AR002012A1 (es) 1994-12-22 1998-01-07 Smithkline Beecham Plc Un compuesto, una composicion farmaceutica que lo comprende, su uso, metodo de tratamiento terapeutico, metodo para la preparacion del compuesto.
CH690264A5 (fr) 1995-06-30 2000-06-30 Symphar Sa Dérivés aminophosphonates substitués, leur procédé de préparation et leur utilisation pour la préparation de compositions pharmaceutiques.
KR19990028630A (ko) 1995-07-01 1999-04-15 데이비드 로버츠 아테롬성 동맥경화증을 치료하기 위한 아제티디논 유도체
CA2233300A1 (en) 1995-09-29 1997-04-10 Christopher Donald Southan A paf-acetylhydrolase and use in therapy
JP2000505063A (ja) 1995-12-08 2000-04-25 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー アテローム性動脈硬化症の治療のためのアゼチジノン化合物
JP2000502079A (ja) 1995-12-08 2000-02-22 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー アテローム性動脈硬化症の治療のための単環β―ラクタム誘導体
GB9608649D0 (en) 1996-04-26 1996-07-03 Smithkline Beecham Plc Novel compounds
AU2698697A (en) 1996-04-26 1997-11-19 Smithkline Beecham Plc Azetidinone derivatives for the treatment of atherosclerosis
GB9626615D0 (en) 1996-12-20 1997-02-05 Symphar Sa Novel compounds
GB9626536D0 (en) 1996-12-20 1997-02-05 Symphar Sa Novel compounds
GB9626616D0 (en) 1996-12-20 1997-02-05 Symphar Sa Novel compounds
JP2001526648A (ja) 1997-04-22 2001-12-18 コセンシス・インコーポレイテッド 炭素環及びヘテロ環で置換されたセミカルバゾン及びチオセミカルバゾン、及びその使用
JP2001522844A (ja) * 1997-11-06 2001-11-20 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ピリミジノン化合物およびそれを含有する医薬組成物
GB9910079D0 (en) 1999-05-01 1999-06-30 Smithkline Beecham Plc Novel compounds
JP3757703B2 (ja) 1999-09-22 2006-03-22 凸版印刷株式会社 再封可能な開口維持部材付パウチ
GB0024807D0 (en) 2000-10-10 2000-11-22 Smithkline Beecham Plc Novel compounds
GB0024808D0 (en) 2000-10-10 2000-11-22 Smithkline Beecham Plc Novel compounds
AU2002228922A1 (en) * 2000-12-12 2002-06-24 Cytovia, Inc. Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators of caspases and inducers of apoptosis and the use thereof
BRPI0208811B8 (pt) * 2001-04-10 2021-05-25 Pfizer derivados de pirazol, seu uso e processo de preparação, bem como composição farmacêutica compreendendo os mesmos
GB0119795D0 (en) 2001-08-14 2001-10-03 Smithkline Beecham Plc Novel process
GB0119793D0 (en) 2001-08-14 2001-10-03 Smithkline Beecham Plc Novel compounds
HN2002000317A (es) * 2001-11-02 2003-05-21 Pfizer Inhibidores de pde9 para tratamiento de trastornos cardiovasculares
GB0127139D0 (en) 2001-11-10 2002-01-02 Smithkline Beecham Novel compounds
GB0127143D0 (en) 2001-11-10 2002-01-02 Smithkline Beecham Novel compounds
GB0127141D0 (en) 2001-11-10 2002-01-02 Smithkline Beecham Plc Novel compounds
GB0127140D0 (en) 2001-11-10 2002-01-02 Smithkline Beecham Novel compounds
GB0208279D0 (en) 2002-04-10 2002-05-22 Glaxo Group Ltd Novel compounds
GB0208280D0 (en) 2002-04-10 2002-05-22 Glaxo Group Ltd Novel compounds
EP1644353A1 (de) 2003-07-02 2006-04-12 Bayer HealthCare AG Amid-substituierte 1, 2, 4-triazin-5 (2h) - one zur behandlung von chronisch inflammatorischen krankheiten
DE102004061009A1 (de) 2004-12-18 2006-06-22 Bayer Healthcare Ag Substituierte 1,2,4-Triazin-5(2H)-one
DE102004061008A1 (de) 2004-12-18 2006-06-22 Bayer Healthcare Ag 3-Arylalkyl- und 3-Heteroarylalkyl-substituierte 1,2,4-Triazin-5(2H)-one
US20080090851A1 (en) 2006-10-13 2008-04-17 Colin Andrew Leach Bicyclic Heteroaromatic Compounds
EP2083625A4 (en) 2006-10-13 2011-10-19 Glaxo Group Ltd BICYCLIC HETOROAROMATIC COMPOUNDS
US20080090852A1 (en) 2006-10-13 2008-04-17 Colin Andrew Leach Bicyclic Heteroaromatic Compounds
US7705005B2 (en) 2006-10-13 2010-04-27 Glaxo Group Limited Bicyclic heteroaromatic compounds
US20080279846A1 (en) 2007-05-11 2008-11-13 Thomas Jefferson University Methods of treatment and prevention of neurodegenerative diseases and disorders
JP5437996B2 (ja) 2007-05-11 2014-03-12 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 皮膚潰瘍の治療方法
US8962633B2 (en) 2007-05-11 2015-02-24 Thomas Jefferson University Methods of treatment and prevention of metabolic bone diseases and disorders
CN103347864B (zh) * 2010-12-06 2016-08-10 葛兰素集团有限公司 用于治疗由Lp-PLA2介导的疾病或病症的嘧啶酮化合物
EP2649050A4 (en) * 2010-12-06 2014-04-23 Glaxo Group Ltd LINKS

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000010980A1 (en) * 1998-08-21 2000-03-02 Smithkline Beecham Plc Pyrimidinone derivatives for the treatment of atherosclerosis
CN1358175A (zh) * 1999-05-01 2002-07-10 史密丝克莱恩比彻姆有限公司 嘧啶酮化合物
WO2000068208A1 (en) * 1999-05-05 2000-11-16 Smithkline Beecham Plc Pyrimidinones derivatives for the treatment of atherosclerosis
CN1418199A (zh) * 2000-02-16 2003-05-14 史密斯克莱·比奇曼公司 作为ldl－pla2抑制剂的嘧啶－4－酮衍生物

Also Published As

Publication number Publication date
ES2559224T3 (es) 2016-02-11
US20140113922A1 (en) 2014-04-24
CN103347864A (zh) 2013-10-09
IL226473A0 (en) 2013-07-31
ZA201303560B (en) 2016-01-27
CA2820408C (en) 2018-03-06
BR112013013898B1 (pt) 2021-10-13
KR20130125784A (ko) 2013-11-19
UY33766A (es) 2012-06-29
KR101861883B1 (ko) 2018-05-28
SG190830A1 (en) 2013-07-31
AR084153A1 (es) 2013-04-24
US20120142717A1 (en) 2012-06-07
WO2012076435A1 (en) 2012-06-14
JP2013544860A (ja) 2013-12-19
US9174968B2 (en) 2015-11-03
DOP2013000130A (es) 2013-11-30
EP2649053B1 (en) 2015-11-04
PH12013501089A1 (en) 2013-07-08
CR20130264A (es) 2013-11-08
BR112013013898A2 (pt) 2016-07-26
PE20140421A1 (es) 2014-04-26
EP2649053A1 (en) 2013-10-16
TW201307324A (zh) 2013-02-16
AU2011340690C1 (en) 2016-03-10
CA2820408A1 (en) 2012-06-14
EA023796B1 (ru) 2016-07-29
US20150099756A1 (en) 2015-04-09
AU2011340690A1 (en) 2013-05-02
JP5886310B2 (ja) 2016-03-16
CL2013001604A1 (es) 2014-07-25
EA201390826A1 (ru) 2013-11-29
MX2013006342A (es) 2013-08-26
CO6801726A2 (es) 2013-11-29
AU2011340690B2 (en) 2015-08-13
US20130252963A1 (en) 2013-09-26
US8637536B2 (en) 2014-01-28

Similar Documents

Publication Publication Date Title
CN103347864B (zh) 用于治疗由Lp-PLA2介导的疾病或病症的嘧啶酮化合物
US8871928B2 (en) Tricyclic compounds, preparation methods, and their uses
AU2012289492B2 (en) 2,3-dihydroimidazo[1,2-c] pyrimidin-5(1H)-one compounds use as Lp-PLA2 inhibitors
CN105008368A (zh) 基于2,3-二氢咪唑并[1,2-c]嘧啶-5(1H)-酮的脂蛋白相关磷脂酶A2(Lp-PLA2)抑制剂
US8859573B2 (en) Pyrimidinone and pyridinone compounds for use in the treatment of diseases or conditions mediated by Lp-PLA2
US20080221103A1 (en) New heterocyclic compounds
CN103827118B (zh) 双环嘧啶酮化合物
CN103827116B (zh) 用作LP-PLA2抑制剂的2,3-二氢咪唑并[1,2-c]嘧啶-5(1H)-酮化合物
CN104478812A (zh) 用于治疗由Lp-PLA2介导的疾病或病症的嘧啶酮化合物
CN105008365B (zh) 化合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160810